Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 180 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción GNFT?
El precio actual de GNFT es de $4.17, ha decreased un 1.65% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Genfit SA?
Genfit SA pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Genfit SA?
La capitalización bursátil actual de Genfit SA es $208.5M
¿Es Genfit SA una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 8 analistas han realizado calificaciones de análisis para Genfit SA, incluyendo 8 fuerte compra, 4 compra, 1 mantener, 0 venta, y 8 fuerte venta
